+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06567743

Phase 2 Open-Label Study Evaluating Cretostimogene Grenadenorepvec Safety and Efficacy in High-Risk Non-Muscle-Invasive Bladder Cancer

Led by CG Oncology, Inc. · Updated on 2026-09-03

325

Participants Needed

80

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Cretostimogene Grenadenorepvec in people with high-risk non-muscle-invasive bladder cancer NMIBC. This Phase 2, multi-arm, open-label study includes participants who are either new to Bacillus Calmette-Guerin BCG treatment, previously treated with BCG, or unresponsive to BCG. The study aims to compare different administration methods and combinations with gemcitabine to better understand treatment options for this condition. Participants are divided into several groups based on their disease status and prior BCG treatment. The study drug Cretostimogene is administered directly into the bladder weekly for six weeks as an induction course, followed by reinduction for certain participants. Maintenance treatment involves cycles of three weekly doses every three months in the first year and every six months in the second year, with an optional extension to the third year. Some groups receive Cretostimogene alone, while others receive it combined with gemcitabine through alternative instillation methods. Participants will have their disease status monitored through urine tests, bladder visualizations like cystoscopy, upper urinary tract assessments, and biopsies if needed every three months for two years, then every six months for up to an additional two years or until disease recurrence. The study measures include complete response rates, event-free survival, and safety outcomes over periods ranging from weeks to 48 months. Overall participation may last several years, with careful follow-up to assess treatment impact and safety.

CONDITIONS

Brief Title

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Research Team

R

Rebecca Tregunna, MD

P

Pat Keegan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here